Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FB(ePEG12)12-Ex4
- Development stage
- Unknown
- Lead developer
- Xiamen University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
18F-FB(ePEG12)12-Ex4 is a fluorine-18 labeled radiopharmaceutical designed for positron emission tomography (PET) imaging of the glucagon-like peptide-1 receptor (GLP-1R). The molecule consists of the GLP-1R agonist Exendin-4, a 39-amino acid peptide, which is conjugated to a [18F]fluorobenzoyl (FB) prosthetic group via a 12-unit polyethylene glycol (ePEG12) linker. The conjugation typically occurs at the Lysine-12 (K12) residue of the peptide, which preserves the binding affinity for GLP-1R. This tracer is primarily developed for the localization of insulinomas (insulin-secreting tumors) and the non-invasive quantification of pancreatic beta-cell mass. The inclusion of the PEG linker enhances the tracer's pharmacokinetic properties by increasing hydrophilicity, which reduces non-specific uptake in the liver and promotes rapid renal clearance, thereby improving the target-to-background ratio in clinical imaging.
- Other names
- 18F-labeled FB-ePEG12-Exendin-4Fluorine-18 fluorobenzoyl-ePEG12-exendin-4Fluorine18 fluorobenzoyl-ePEG12-exendin-4Fluorine 18 fluorobenzoyl-ePEG12-exendin-418F-FB-ePEG12-Ex4
02
Targets
Beyond the preview
Go deeper on 18F-FB(ePEG12)12-Ex4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-FB(ePEG12)12-Ex4.